Citizens Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $93
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.
Citizens analyst Jason N. Butler maintains Halozyme Therapeutics (NASDAQ:HALO) with a Market Outperform and raises the price target from $92 to $93.